American Journal of Medical Case Reports. 2015, 3(5), 144-145
DOI: 10.12691/AJMCR-3-5-7
Facial Herpes Simplex Virus Type 1 Infection in a Patient with Multiple Sclerosis on Fingolimod
Racosta Juan Manuel1, McEwan Lynn1, Kremenchutzky Marcelo Carlos1 and Morrow Sarah Anne1,
1University of Western Ontario, London, Ontario
Pub. Date: April 23, 2015
Cite this paper
Racosta Juan Manuel, McEwan Lynn, Kremenchutzky Marcelo Carlos and Morrow Sarah Anne. Facial Herpes Simplex Virus Type 1 Infection in a Patient with Multiple Sclerosis on Fingolimod.
American Journal of Medical Case Reports. 2015; 3(5):144-145. doi: 10.12691/AJMCR-3-5-7
Abstract
Fingolimod is an oral disease-modifying therapy for relapsing multiple sclerosis widely used in Canada as a second-line therapy. Fingolimod increases the risk of infections given its dose-dependent reduction of peripheral lymphocytes, due to the reversible sequestration in lymphoid tissues. We present a case of disseminated facial Herpes Simplex Virus type I infection in a patient using fingolimod, with an atypical distribution of the eruption, likely due to the concomitant exposure to sunlight and application of sunscreen. This case report provides insight about a novel mechanism of disseminationof Herpes Simplex Virus type I, which generally enters damaged epithelium or mucosal surfaces secondary to abrasions or trauma. Since Herpes Simplex Virus type I infection tends to disseminate and is accompanied by visceral involvement in immunosuppressed patients, close surveillance of viral infections and the prompt administration of full-dose antiviral therapy in this population is advised.
Keywords
multiple sclerosis, fingolimod; herpes simplex, infection, adverse effect
Copyright
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
http://creativecommons.org/licenses/by/4.0/
References
[1] | Cohen J.A., Chun J. "Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis", Annals of Neurology, 69(5).759-777. May. 2011. |
|
[2] | Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., et al. "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis", New England Journal of Medicine, 362(5).387-401. Feb.2010. |
|
[3] | Calabresi P.A., Radue E.W., Goodin D., Jeffery D., Rammohan K.W., Reder A.T., et al. "Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial", Lancet Neurology, 13(6).545-556. Jun.2014. |
|
[4] | Khatri B., Barkhof F., Comi G., Hartung H.P., Kappos L., Montalban X., et al. "Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study",Lancet Neurology, 10(6).520-529.Jun.2011. |
|
[5] | Maalouf E., Moutran R., Maatouk I. "Disseminated primary HSV-2 infection of the face",Dermatology Online Journal, 18(6).15. Jun.2012. |
|
[6] | Brinkmann V., Chen S., Feng L., Pinschewer D., Nikolova Z., Hof R.. "FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression", Transplantation Proceedings, 33(1-2).530-531. Feb-Mar. 2001. |
|
[7] | Pinschewer D.D., Ochsenbein A.F., Odermatt B., Brinkmann V., Hengartner H., Zinkernagel R.M. "FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory",Journal of Immunology, 164(11).5761-70.Jun. 2000. |
|